Fosun Kaili (Shanghai) Biotechnology Co., Ltd. Increases Registered Capital to RMB 2.23 Billion, Up by Approximately 16%

Tianyancha App shows that on December 5, Fosun Kite Biotechnology Co., Ltd. underwent industrial and commercial changes, adding Shenzhen Pengfu Bio-pharmaceutical Industry Private Equity Investment Fund Partnership (Limited Partnership), Shenzhen Pingshan District Guiding Fund Investment Co., Ltd., and Shanghai Fureyi Enterprise Consulting Management Partnership (Limited Partnership) as shareholders. Meanwhile, the registered capital increased from approximately 1.92 billion RMB to about 2.23 billion RMB, with an increase of approximately 16%.

Fosun Kite Biotechnology Co., Ltd. was established in April 2017, with Wenjie Zhang as the legal representative. The business scope includes pharmaceutical production, contract manufacturing of pharmaceuticals, pharmaceutical import and export, medical research and experimental development, cell technology R&D and application, human gene diagnosis and treatment technology development, human stem cell technology development and application, etc. Shareholder information shows that the company is held by Shanghai Fosun Pharmaceutical Development Co., Ltd.Fosun PharmaShanghai Fosun Pharmaceutical Development Co., Ltd., Shanghai Fosun Enterprise Consulting Management Partnership (Limited Partnership), and the aforementioned new shareholders hold shares jointly.